CoChat

Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus

Chen, Xiao‐Wu, He, Zhi‐Xu, Zhou, Zhi‐Wei, Yang, Tianxin, Zhang, Xueji, Yang, Yin‐Xue, Duan, Wei, Zhou, Shu‐Feng · 2015 · Clinical and Experimental Pharmacology and Physiology
Cited by 86

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Summary: Dipeptidyl peptidase‐4 (DPP‐4) inhibitors are a class of oral antidiabetic drugs that improve glycaemic control without causing weight gain or increasing hypoglycaemic risk in patients with type 2 diabetes mellitus (T2DM). The eight available DPP‐4 inhibitors, including alogliptin, anagliptin, gemigliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin, and vildagliptin, are small molecules used orally with identical mechanism of action and similar safety profiles in patients with T2DM. DPP‐4 inhibitors may be used as monotherapy or in double or triple combination with other oral glucose‐lowering agents such as metformin, thiazolidinediones, or sulfonylureas. Although DPP‐4 inhibitors have the same mode of action, they differ by some important pharmacokinetic and pharmacodynamic properties that may be clinically relevant in some patients. The main differences between the eight gliptins include: potency, target selectivity, oral bioavailability, elimination half‐life, binding to plasma proteins, metabolic pathways, formation of active metabolite(s), main excretion routes, dosage adjustment for renal and liver insufficiency, and potential drug‐drug interactions. The off‐target inhibition of selective DPP‐4 inhibitors is responsible for multiorgan toxicities such as immune dysfunction, impaired healing, and skin reactions. As a drug class, the DPP‐4 inhibitors have become accepted in clinical practice due to their excellent tolerability profile, with a low risk of hypoglycaemia, a neutral effect on body weight, and once‐daily dosing. It is unknown if DPP‐4 inhibitors can prevent disease progression. More clinical studies are needed to validate the optimal regimens of DPP‐4 inhibitors for the management of T2DM when their potential toxicities are closely monitored.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/1440-1681.12455

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 86

Metadata

Authors
Chen, X., He, Z., Zhou, Z., Yang, T., Zhang, X., Yang, Y., Duan, W., & Zhou, S.
Venue
Clinical and Experimental Pharmacology and Physiology
Publisher
Wiley
Published
2015-09-15
Volume
42
Issue
10
Pages
999-1024
ISSN
  • 0305-1870 (ISSN-L)
  • 1440-1681
OpenAlex
W1681939708
Cited by
86
References
13
FWCI
6.33
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1111/1440-1681.12455
The paper
Chen, X., He, Z., Zhou, Z., Yang, T., Zhang, X., Yang, Y., Duan, W., & Zhou, S. (2015). Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.12455

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.